L Tugume1, B M Morawski2,3, M Abassi1,2, N C Bahr1,2,4, R Kiggundu1, H W Nabeta1, K H Hullsiek5, K Taseera6, A K Musubire1,2, C Schutz7, C Muzoora6, D A Williams1,2, M A Rolfes8, G Meintjes7,9, J Rhein1,2, D B Meya1,2,10, D R Boulware2,4. 1. Infectious Disease Institute, Makerere University, Kampala, Uganda. 2. Division of Infectious Diseases and International Medicine, Department of Medicine, University of Minnesota, Minneapolis, MN, USA. 3. Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, MN, USA. 4. Center for Infectious Diseases & Microbiology Translational Research, University of Minnesota, Minneapolis, MN, USA. 5. Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN, USA. 6. Department of Medicine, Mbarara University of Science and Technology, Mbarara, Uganda. 7. Clinical Infectious Diseases Research Initiative, Institute of Infectious Disease and Molecular Medicine and Department of Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa. 8. Epidemiologic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, GA, USA. 9. Department of Medicine, Imperial College London, London, UK. 10. Department of Medicine, Faculty of Health Sciences, Makerere University, Kampala, Uganda.
Abstract
OBJECTIVES: Anaemia represents a common toxicity with amphotericin B-based induction therapy in HIV-infected persons with cryptococcal meningitis. We sought to examine the impact of amphotericin-related anaemia on survival. METHODS: We used data from Ugandan and South African trial participants to characterize the variation of haemoglobin concentrations from diagnosis to 12 weeks post-diagnosis. Anaemia severity was classified based on the haemoglobin concentration at cryptococcal meningitis diagnosis, and nadir haemoglobin values during amphotericin induction. Cox proportional hazard models were used to estimate 2- and 10-week mortality risk. We also estimated 10-week mortality risk among participants with nadir haemoglobin < 8.5 g/dL during amphotericin induction and who survived ≥ 2 weeks post-enrolment. RESULTS: The median haemoglobin concentration at meningitis diagnosis was 11.5 g/dL [interquartile range (IQR) 9.7-13 g/dL; n = 311] with a mean decline of 4.2 g/dL [95% confidence interval (CI) -4.6 to -3.8; P < 0.001; n = 148] from diagnosis to nadir value among participants with baseline haemoglobin ≥ 8.5 g/dL. The median haemoglobin concentration was 8.1 g/dL (IQR 6.5-9.5 g/dL) at 2 weeks, increasing to 9.4 g/dL (IQR 8.2-10.9 g/dL) by 4 weeks and continuing to increase to 12 weeks. Among participants with haemoglobin < 8.5 g/dL at diagnosis, mortality risk was elevated at 2 weeks [hazard ratio (HR) 2.7; 95% CI 1.5-4.9; P < 0.01] and 10 weeks (HR 1.8; 95% CI 1.1-2.2; P = 0.03), relative to those with haemoglobin ≥ 8.5 g/dL. New-onset anaemia occurring with amphotericin therapy did not have a statistically significant association with 10-week mortality (HR 2.0; 95% CI 0.5-9.1; P = 0.4). CONCLUSIONS: Amphotericin induced significant haemoglobin declines, which were mostly transient and did not impact 10-week mortality. Individuals with moderate to life-threatening anaemia at baseline had a higher mortality risk at 2 and 10 weeks post-enrolment.
OBJECTIVES:Anaemia represents a common toxicity with amphotericin B-based induction therapy in HIV-infectedpersons with cryptococcal meningitis. We sought to examine the impact of amphotericin-related anaemia on survival. METHODS: We used data from Ugandan and South African trial participants to characterize the variation of haemoglobin concentrations from diagnosis to 12 weeks post-diagnosis. Anaemia severity was classified based on the haemoglobin concentration at cryptococcal meningitis diagnosis, and nadir haemoglobin values during amphotericin induction. Cox proportional hazard models were used to estimate 2- and 10-week mortality risk. We also estimated 10-week mortality risk among participants with nadir haemoglobin < 8.5 g/dL during amphotericin induction and who survived ≥ 2 weeks post-enrolment. RESULTS: The median haemoglobin concentration at meningitis diagnosis was 11.5 g/dL [interquartile range (IQR) 9.7-13 g/dL; n = 311] with a mean decline of 4.2 g/dL [95% confidence interval (CI) -4.6 to -3.8; P < 0.001; n = 148] from diagnosis to nadir value among participants with baseline haemoglobin ≥ 8.5 g/dL. The median haemoglobin concentration was 8.1 g/dL (IQR 6.5-9.5 g/dL) at 2 weeks, increasing to 9.4 g/dL (IQR 8.2-10.9 g/dL) by 4 weeks and continuing to increase to 12 weeks. Among participants with haemoglobin < 8.5 g/dL at diagnosis, mortality risk was elevated at 2 weeks [hazard ratio (HR) 2.7; 95% CI 1.5-4.9; P < 0.01] and 10 weeks (HR 1.8; 95% CI 1.1-2.2; P = 0.03), relative to those with haemoglobin ≥ 8.5 g/dL. New-onset anaemia occurring with amphotericin therapy did not have a statistically significant association with 10-week mortality (HR 2.0; 95% CI 0.5-9.1; P = 0.4). CONCLUSIONS:Amphotericin induced significant haemoglobin declines, which were mostly transient and did not impact 10-week mortality. Individuals with moderate to life-threatening anaemia at baseline had a higher mortality risk at 2 and 10 weeks post-enrolment.
Authors: Annemarie E Brouwer; Adul Rajanuwong; Wirongrong Chierakul; George E Griffin; Robert A Larsen; Nicholas J White; Thomas S Harrison Journal: Lancet Date: 2004-05-29 Impact factor: 79.321
Authors: Megan E O'Brien; Roland Kupka; Gernard I Msamanga; Elmar Saathoff; David J Hunter; Wafaie W Fawzi Journal: J Acquir Immune Defic Syndr Date: 2005-10-01 Impact factor: 3.731
Authors: Benjamin J Park; Kathleen A Wannemuehler; Barbara J Marston; Nelesh Govender; Peter G Pappas; Tom M Chiller Journal: AIDS Date: 2009-02-20 Impact factor: 4.177
Authors: Paul A Volberding; Alexandra M Levine; Douglas Dieterich; Donna Mildvan; Ronald Mitsuyasu; Michael Saag Journal: Clin Infect Dis Date: 2004-04-27 Impact factor: 9.079
Authors: Arthur T Jackson; Jesse C Nussbaum; Jacob Phulusa; Dan Namarika; Maria Chikasema; Creto Kanyemba; Joseph N Jarvis; Shabbar Jaffar; Mina C Hosseinipour; Charles van der Horst; Thomas S Harrison Journal: AIDS Date: 2012-07-17 Impact factor: 4.177
Authors: Joseph N Jarvis; Tihana Bicanic; Angela Loyse; Daniel Namarika; Arthur Jackson; Jesse C Nussbaum; Nicky Longley; Conrad Muzoora; Jacob Phulusa; Kabanda Taseera; Creto Kanyembe; Douglas Wilson; Mina C Hosseinipour; Annemarie E Brouwer; Direk Limmathurotsakul; Nicholas White; Charles van der Horst; Robin Wood; Graeme Meintjes; John Bradley; Shabbar Jaffar; Thomas Harrison Journal: Clin Infect Dis Date: 2013-12-06 Impact factor: 9.079
Authors: Asgeir Johannessen; Ezra Naman; Bernard J Ngowi; Leiv Sandvik; Mecky I Matee; Henry E Aglen; Svein G Gundersen; Johan N Bruun Journal: BMC Infect Dis Date: 2008-04-22 Impact factor: 3.090
Authors: Caleb Skipper; Mark R Schleiss; Ananta S Bangdiwala; Nelmary Hernandez-Alvarado; Kabanda Taseera; Henry W Nabeta; Abdu K Musubire; Sarah M Lofgren; Darin L Wiesner; Joshua Rhein; Radha Rajasingham; Charlotte Schutz; Graeme Meintjes; Conrad Muzoora; David B Meya; David R Boulware Journal: Clin Infect Dis Date: 2020-07-27 Impact factor: 9.079
Authors: Matthew F Pullen; Katherine Huppler Hullsiek; Joshua Rhein; Abdu K Musubire; Lillian Tugume; Edwin Nuwagira; Mahsa Abassi; Kenneth Ssebambulidde; Edward Mpoza; Ruben Kiggundu; Andrew Akampurira; Henry W Nabeta; Charlotte Schutz; Emily E Evans; Radha Rajasingham; Caleb P Skipper; Katelyn A Pastick; Darlisha A Williams; Bozena M Morawski; Ananta S Bangdiwala; Graeme Meintjes; Conrad Muzoora; David B Meya; David R Boulware Journal: Clin Infect Dis Date: 2020-10-23 Impact factor: 9.079
Authors: John W Diehl; Katherine H Hullsiek; Michael Okirwoth; Nicole Stephens; Mahsa Abassi; Joshua Rhein; David B Meya; David R Boulware; Abdu K Musubire Journal: Open Forum Infect Dis Date: 2018-05-08 Impact factor: 3.835
Authors: Anna M Stadelman; Kenneth Ssebambulidde; Lillian Tugume; Katelyn A Pastick; Kathy Huppler Hullsiek; Sarah Lofgren; Edwin Nuwagira; Emily E Evans; Darlisha A Williams; Conrad Muzoora; David B Meya; Radha Rajasingham; Joshua Rhein; David R Boulware Journal: Med Mycol Date: 2021-07-06 Impact factor: 4.076
Authors: Morris K Rutakingirwa; Fiona V Cresswell; Richard Kwizera; Kenneth Ssebambulidde; Enock Kagimu; Edwin Nuwagira; Lillian Tugume; Edward Mpoza; Joanna Dobbin; Darlisha A Williams; Conrad Muzoora; David B Meya; David R Boulware; Kathy H Hullsiek; Joshua Rhein Journal: J Clin Med Date: 2020-03-13 Impact factor: 4.241